Abstract: Ampicillin/Sulbactam is a combination of antibiotics made up of ampicillin, a betalactam and Sulbactam, a betalactamase inhibitor introduced in the eighties. The most frequent used combination is Ampicillin/Sulbactam (ratio 2:1) although the two agents are not synergetic. Ampicillin/Sulbactam has a wide range of antibacterial activity that includes Gram-positive and Gram-negative aerobic and anaerobic bacteria. However, the drug is not active against Pseudomonas aeruginosa and pathogens producing extended-spectrum β-lactamases. The combination could be considered particularly active against Acinetobacter baumannii infections due to the intrinsic activity of Sulbactam. In clinical trials, sultamicillin has proved clinically and bacteriologically effective against a severe bacterial infections, including mild upper and lower respiratory tract infections, meningitis, intra-abdominal, diabetic foot and skin and soft tissue infections, etc. Furthermore, adverse effects rarely occur with the diarrhoea to represent the most commonly reported. Moreover, it seems to represent the alternative of choice for the treatment of A. baumannii infections for carbapenem-resistant strains in the nosocomial setting. This review focuses on the efficacy of the β-lactam ampicillin co-administered with the β-lactamase inhibitor sulbactam, parenterally (Ampicillin/Sulbactam), for the treatment of bacterial infections.
Introduction
Ampicillin/Sulbactam is a combination of the common penicillin-derived antibiotic ampicillin and sulbactam, an inhibitor of bacterial β-lactamase developed in the eighties. 1, 2 Ampicillin/Sulbactam combination is the most frequently used although both agents are not synergetic. Studies have been conducted to examine its effectiveness in several types of infection. [3] [4] [5] [6] From thepastdecade,conductedclinicalfindingsconfirm the results of numerous older studies and together provide good evidence to support the frequent use of Ampicillin/Sulbactam in hospital-and communityacquired infections in both, adults and children.
On the another hand, the multidrug-resistant microorganism appearance, especially multidrug-resistant Acinetobacter spp, makes the treatment of nosocomialinfectionsmoredifficultbeingimperativeanew agent search and old drugs use as optimal treatment of these multidrug-resistant organisms.
Ampicillin/Sulbactam may represent the alternative choice for the treatment of A. baumannii infections for carbapenem-resistant strains in the nosocomialsetting.Thispaperfocusesontheefficacy of the β-lactam ampicillin co-administered with the β-lactamase inhibitor sulbactam, parenterally (Ampicillin/Sulbactam), for severe bacterial infection with specially attention in multidrug resistant infections treatment.
Mechanism of Action and Antimicrobial Spectrum
Ampicillin inhibits bacterial cell wall synthesis by binding Penicillin Binding Proteins (PBPs) which are the enzymes responsible for the cell wall structure formation. It acts as a structural analogue of acyl-D-alanyl-D alanine and acylates the transpeptidase enzyme responsible for the final stage in the peptidoglycan formation, the main component of the cell wall. 7 Sulbactamisapotent,highlyspecificinhibitorof β-lactamases (most plasma-mediated and some chromosomal β-lactamases) obtained by the oxidation of thiazolidine sulfur of penicillanic acid. 8 Sulbactam doesn't enhance bactericidal activity of Ampicillin but prevents it from being destroyed by β-lactamase producing bacteria as it inhibits hydrolysis of the latter by β-lactamases. As a result, the antimicrobial activity of ampicillin, when combined with sulbactam increases by 4-32 folds and its spectrum is extended to include β-lactamase-producing strains of many common pathogens 6 because it protects ampicillin from hydrolysis by β-lactamases. 9 Sulbactam joins with the β-lactamases forming an acyl enzyme for reaction with the active site serine hydroxyl group. This intermediate can undergo (a) deacylation and hydrolysis of the enamine liberated, which leads to the formation of smaller products; (b) a tautomerisation to enamine leading to a transiently inhibited form of the enzyme and; (c) a transamination reaction or reaction with serine 130 that leads to an irreversibly inhibited enzyme form. 3, 10 Sulbactam distinguishes from other available β-lactamase inhibitors due to the high level of antimicrobial activity against Neisseria spp, Bacteroides fragilis and Acinetobacter species, organisms against which most cephalosporins display little or no activity. In addition, the antimicrobial spectrum of 13 It has no activity against Pseudomonas aeruginosa and extended-spectrum β-lactamases Enterobacters. The Ampicillin/Sulbactam resistance rates against imipenem-susceptible and -resistant Acinetobacter baumannii were 23.5 and 30%, respectively.
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Ampicillin/Sulbactam Pharmacokinetics and Pharmacodynamics
Intravenous or oral sulbactam has a similar pharmacokineticprofilethani.v.ororalampicillin,whichfavours their combination into a single formulation. 3, 5, 15, 16 The ampicillin and sulbactam pharmacokinetics are linear uptoatleast1000mgandtheprofileofi.v.ampicillin is unaffected co-administered with sulbactam. On theotherhand,sulbactamprofileremainsunchanged after co-administration of ampicillin. Both drugs have a half life of 1 hour, and .75% is excreted unchanged in the urine in both cases. 3, 5 Ampicillin is partially (40%) absorbed after oral administration, and Sulbactam oral absorption is very poor. Ampicillin/Sulbactam is not well absorbed after oral administration. This problem was overcome with the combination of ampicillin and sulbactam in one oral prodrug, sultamicillin. This double ester is well absorbed in the intestine (80% bioavailability) and rapidly hydrolysed during absorption from the gastrointestinal tract to provide high levels (in equimolar quantities) of ampicillin and sulbactam and increases the bioavailability of ampicillin when administered as sultamicillin than when administered alone. 3, 5, 6 Comparative data suggest that there is a prolongation of Ampicillin/Sulbactam antimicrobial activity as age increases due to the area under the serum concentration-time curve half life, serum maximum concentration and decreased total clearance in older age groups. 17 Thepharmacokineticprofilesofampicillin and sulbactam in children are the same as those in adults. In children, age appeared to have no effect on the pharmacokinetics of Ampicillin or Sulbactam and the results were also independent of dose and gender. 6 Although the elimination half-lives of both ampicillin and sulbactam take 1 h, sultamicillin has the advantage that it can be given twice or three times a day. This leads to high serum and tissue concentrations sustained above MICs of many common pathogens. 15, 16 The protein binding of ampicillin and sulbactam in serum is moderate (38% for sulbactam and 28% for ampicillin). Both ampicillin and sulbactam are arranged extensively to a variety of tissues and body fluids(e.g.intestinalmucosa,prostaticandappendiceal tissue, sputum, peritoneal fluid, peritonsillar abscess pus,andcerebrospinalfluidinthepresenceofinflamed meninges). 6, 18 Data on sulbactam penetration into tissues/fluidsinclude:intraperitonealfluid(60%),sputum (12%-14%),cerebrospinalfluid(11%-34%),intenstinal mucosa (0.7%-0.8%) and myometrium (64%). 15, 16 Approximately 75 to 85% of both ampicillin and sulbactam are primarily eliminated by renal excretion and the half-life and serum concentrations in patients with impaired renal function are increased. Accordingly, the frequency of dosing is reduced routinely (from three or four times daily to twice or once daily) in patients with renal impairment. 3 It should be administered with caution to infants aged ,1 week and to premature neonates as half-time is significantlyincreasedforbothbecauseoftheimmature renal function in neonates and newborn. 
Lower respiratory tract infections and aspiration pneumonia
Bacterial respiratory tract infections continue to represent a major source of morbidity and mortality, despite continuing improvements in diagnosis and the development of new kinds of antibiotic. Unfortunately, the emergence of β-lactamase-mediated bacterial resistance among many common pathogens has threatened the usefulness of β-lactam agents. 6, 20, 21 In the case of IV Ampicillin/Sulbactam, many clinical trials have shown its effectiveness in the treatment inadultswithseriousnon-specificlowerrespiratory tract infections (LRTIs) ( Table 1) .
Ampicillin/sulbactam (2-12 gr./day), followed by oral sultamicillin in some cases, has been compared with imipenem/cilastatin, second and third generation cephalosporins, ticarcillin/clavulanic, clindamycin(withorwithoutcephalosporin),ormoxifloxacin for the treatment of community-or hospital-acquired lower respiratory tract infections without significantly differences. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] In the review made by Lode 6 in 2001 on the role of Ampicillin/Sulbactam in the treatment of bacterial respiratory tract infections in adult patients, based on 20 researches comparatives and two meta-analyses published in the 1980s and 1990s, the clinical success rates were in the range of 84%-100% and bacteriological eradication rates ranged from 44% to 100%. In recent studies (mainly comparative, prospective and randomised) the clinical efficacy (cure or improvement) rates are ranged from62%to100%andbacteriologicalefficacyrates from 58%-100%. [27] [28] [29] These response rates are generally compared with the clinical and bacteriological response rates for the comparators, cefuroxime (41%-95% and 50%-93%), 32, 34, 36 cefotaxime (81 and 48%), 33 cefoxitin (81 and 76%) 25 and mezlocillin (83 and 89%), 35 imipenem (83%), 30 clindamycin (67%) 27 or moxifloxacin (66.7%) 26 (Table 1) . In an open-label, comparative study Ampicillin/Sulbactam and cefuroxime yielded similar clinical responses (98 and 95%, respectively) but the eradication rate for Ampicillin/Sulbactamwassignificantlysuperior(95 versus 50%, P-0.001). 22 However, only the metaanalysis carried out by Zervos et al on the efficacy and safety of Ampicillin/Sulbactam (2/1 or 1/0.5 g IV four times daily) versus second-or third-generation cephalosporins (cefoxitin, cefotaxime, cefuroxime, or cefamandole) showed that the observed rate of clinical cure or improvement was greater for Ampicillin/ Sulbactam than for comparators (93.3 versus 86.6%, P = 0.019), being the rate of clinical cure 60.3 versus 54.6%, P = 0.055. The bacteriological eradication rate was similar for Ampicillin/Sulbactam (85.3%) and comparators (83.5%).
Regarding the efficacy of Ampicillin/Sulbactam compared to another β-lactam/β-lactamase inhibitor combination, a clinical trial of Ampicillin/Sulbactam versus ticarcillin/clavulanic acid recorded a satisfactory clinical response in 83 and 78% of patients with respiratory tract infections, respectively. The correspondingratesofbacteriologicalefficacywere62and 71%. 31 These data suggest that Ampicillin/Sulbactam is as effective as another β-lactam/β-lactamase inhibitor combination in the treatment of lower respiratory tract infection.
Aspiration pneumonia and primary lung abscess are diseases following aspiration of infectious material from the oropharynx or stomach. An antibiotic therapy, also covering anaerobic pathogens, is the chosen treatment. Ampicillin/Sulbactam has been compared to antimicrobials with antianaerobic activity such as clindamycin and imipenem/cilastatin. Cure rates with Ampicillin/Sulbactam in aspiration pneumonia were relatively low in comparison with the cure improvement rates of Ampicillin/Sulbactam in clinical trials of lower respiratory tract infections without aspiration (i.e. 66.7% in two studies. 26, 27 In the prospective, openlabel, randomized, multicenter trial of Ott et al 26 the efficacyofAmpicillin/Sulbactamvs.moxifloxacinin these entities were compared. 139 patients were studied,96ofthemwereevaluableforefficacy,48patients in each treatment group. The overall clinical response rates in both groups were numerically similar (66.7%). Both treatments seem to be clinically effective and safe; however,moxifloxacinshowstheadditionalbenefitof a more convenient (400 mg qd) treatment.
With respect to the treatment doses, some authors have used higher doses of Ampicillin/Sulbactam in aspiration pneumonia. Kadowaki et al 28 administred Ampicillin/Sulbactam in two different dosages protocols: 3 gr. twice a day and 1.5 gr. twice a day and compared them with clindamycin and imipem cilastatin in 100 elderly patients with aspiration pneumonia. Cure rates in patients receiving Ampicillin/Sulbactam 3 gr. were higher (84%) than the rates in patients treated with half dose and comparable with those in the imipem group (88%) which seemed to be the most effective regimen.
The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) 
intra-abdominal infections
Thefirsttreatmentofintra-abdominalinfectionsisthe combination of surgical debridement and antimicrobialtreatmentagainstpolymicrobialflora.Antibiotics used for empiric treatment of community-acquired intra-abdominal infection should be active against gram-negative aerobic enteric facultative bacilli and gram-positive enteric Streptococci.
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Ampicillin/Sulbactam has been compared in patients with intra-abdominal infections versus clindamycin plus gentamicin, cefoxitin, and ampicillin plus clindamycin ( Table 2 ). The differences between the cure rates achieved with each treatment were comparable except in the study conducted by Yellin et al thatshowedsignificantlylowerresultsforAmpicillin/ Sulbactam vs. clindamycin plus gentamicin. [41] [42] [43] Another study 44 assessed the efficacy and cost of Ampicillin/ Sulbactam versus cefoxitin or clindamycin plus gentamicin in patients with various bacterial infections. The study conduced by Messick CR et al 44 41, 42 The clinical success rate (87%) was similar to the most widely studied antibiotics: gentamicin/clindamycin 80%; tobramycin/clindamycin 83%; meropenem 89%; imipenem 85%; aztreonam/ clindamycin 89%; cefoxitin 88%; cefotetan 92%; moxalactam 83%; cefotaxime/metronidazole 87%; and piperacillin/tazobactam 90%.
A Cochrane systematic review 46 of antibiotics for the treatment of secondary peritonitis of gastrointestinal origin showed that there were no differences between treatments in comparison with gentamicin/clindamycin 47 and cefoxitin; 42 however whilst Ampicillin/Sulbactam and gentamicin/clindamycin were equally effective for anaerobe infections, gentamicin/clindamycin was more effective for Pseudomonas infections. 41 The Cochrane review 46 concluded that no specific recommendation couldbemadeinfavourofoneantibioticforthefirstline treatment of secondary peritonitis.
However, the current Infectious Diseases Society of America (IDSA) guidelines 41 did not recommend the use of Ampicillin/Sulbactam in intra-abdominal infections because of high rates of resistance to this agent among community-acquired E. coli (B-II). 48 
Gynaecological/obstetrical infections
Pelvic inflammatory disease includes endometritis, salpingitis, tuboovarian abscess and pelvic peritonitis. Ampicillin/Sulbactam has been compared with cefoxitin in various studies [49] [50] [51] [52] [53] withclinicalefficacy rates between 85%-90% in the group of Ampicillin/ Sulbactamwithoutsignificantlydifferenceswiththe group of cefoxitin (clinical cure rates 85%-95%). In another study clindamycin alone or with gentamicin, cefotetan or cefoxitin and metronidazole with or without gentamicin were compared [54] [55] [56] [57] [58] [59] (Table 3 ). Cure and/or improvement rates ranged from 82% to 100%. Clinical efficacy with Ampicillin/Sulbactam was higher than or equal to cefoxitin, but was inferior to clindamycin plus gentamicin in all relevant studies. Cefotetan and metronidazol plus gentamicinwerefoundtohavethesameclinicalefficacyas ampoicillin/sulbactam in two studies. 55, 56 However, the differences between therapeutic treatments in cure/ improvementrateswerenotstatisticallysignificant.
Ampicillin/Sulbactam is an effective therapy for the treatment of post-operative infections, pelvic inflammatory disease and post-Caesarean and postpartumendometritis,withequivalentclinicalefficacy to other agents, including metronidazole/gentamicin, cefoxitin, cefoxitin/doxycycline, gentamicin/clindamycin and clindamycin.
Diabetic foot infections
Serious lower-limb infections treatment in diabeticscanbedifficult.Factorssuchasthepresenceof polymicrobial infection, underlying or contigous osteomyelitis, hyperglycemia and diabetic sequelae commonly influence their medical and surgical management. 60 Akova et al 61 studied seventy-four patients with diabetic foot infections treated with parenteral Ampicillin/ Sulbactam (1.5 g, q.i.d.) . The result were clinical cure rates of 86% and 100% in patients with osteomyelitis and with soft tissue infection, respectively which indicates that Ampicillin/Sulbactam is safe and effective in the treatment of diabetic foot infections.
A randomized double-blind study compared imipenem 0.5 gr./6 hours and Ampicillin/Sulbactam (3 gr./6 hours) in limb-threatening infections in diabetic patients showed comparable outcomes. Cure rates were 81% for the Ampicillin/Sulbactam group versus 85% for the imipenem group, failure rates were 17% for Ampicillin/Sulbactam versus 13% for imipenem and bacterial eradication was 67% and 75% for Ampicillin/Sulbactam and imipenem respectively. 3, 60 Ampicillin/Sulbactam has been compared with piperacillin/tazobactam, clyndamicin, cefoxitin and linezolid. In the case of piperacillin/tazobactam the clinicalefficacywascomparable(83.1%forAmpicil-lin/Sulbactam vs. 81% for piperacillin/tazobactam). A higher bacteriological success rate was achieved by piperacillin/tazobactam as the most common gramnegative bacterium in this study was P. aeruginosa. 62 Cindamycin compared to cefoxitin showed similar results. 63, 64 Ampicillin/Sulbactam has been compared with linezolid in a randomised, open-label trial, without significantly statistically differences. Higher cure rates were achieved in the linezolid treatment arm than in the Ampicillin/Sulbactam treatment arm in patients with infected ulcers (81% vs. 68% P = 0.018) and in patients without osteomyelitis (87% vs. 72%, P = 0.003). 65 
Skin and soft tissue infections
Ampicillin/Sulbactam has been compared with cefoxitin, 66 cefazolin 67 or clindamycin. Parenteral Ampicillin/Sulbactam was effective in treating various skin and soft tissue infections (Table 4) .
Ampicillin/Sulbactam and cefoxitin were compared in a randomised, double-blind trial in patients with or without history of injection drug abuse who presented skin or another soft tissue infections. These two agents were equally effective for the empirical treatment of skin or another soft tissue infections in both patients. Cure occurred in 89.8% of Ampicillin/ Sulbactam treated patients compared with 93.6% of cefoxitin treated patients. 66 A randomized double blind study in 58 hospitalized patients compared intravenous Ampicillin/ Sulbactam (1 gr/6 hours) with cefazolin 500 mg/6 hours in the treatment of cellulitis and with cefoxitin (1 gr/6 hours). In other skin infections, no statisticallysignificantdifferencesinefficacyorsafety were detected. In patients with cellulitis, Ampicillin/ Sulbactam and cefazolin produced a clinical cure or improvement in 100% and 91.7% of patients res pectively. 67 In other infections the result for Ampicillin/Sulbactam and cefoxitin were 80 and 64.7% respectively. In the case of clindamycin, sixty patients with soft tissue infections received Ampicillin/Sulbactam (2 gr/6 h, n = 30) or clindamycin (600 mg/6 h) plus tobramycin (1.5 mg/Kg/8 h, n = 30). A 93% cure or improvement rate was shown with Ampicillin/ Sulbactam compared with 81% in the clindamycin group. 68 infections due to A. baumannii Ampicillin/Sulbactam may be an effective and safely used therapeutic option to treat severe nosocomial infections caused by multidrug-resistant (MDR) A. baumannii given Sulbactam in-vitro activity against the organism including some carbapenemsresistant strains. 69 Its mechanism of antimicrobial activity against A. baumannii strains is related to its intrinsicaffinityforessentialpenicillin-bindingproteins (PBPs) of these organisms and to alter the permeability of the outer membrane of gram-negative bacilli resulting in the leakage of β-lactamases and thus better penetration by other antibacterial agents. Ampicillin/ Sulbactam was 6 gr and 3 gr respectively and six patients received 12 g and 6 g respectively. The infections were primary bacteraemia (32.5%), pneumonia (30%), urinary tract infection (15%), peritonitis (7.5%) surgical site (7.5%), meningitis (5%) and sinusitis (2.5%). In this case, 67.5% of patients were improved/cured and 17.5% experienced treatment failure. The patients with meningitis did not respond to the treatment.
The intravenous Sulbactam penetrates about 1% through the blood brain barrier, which will increase to32%inthemeningealinflammation.
2,18 Ampicillin/ Sulbactam combination has been used to treat MDR A. baumannii meningitis by some authors in doses of 2 gr/6-8 hours with a mortality of 20%-25%. 4, 18, 70, 71 In our experience of 4 cases treated with 3 gr/8 hour, mortality was 33% without lower evidence than in other treatments except intrathecal colistin intravenously. 18 Within the eight cases published by Jimenez Mejias et al 70 doses of 1 gr/6-8 hours were used producing the death of patients receiving treatment every 8 hours. Nowadays the dose of 2 gr/6 hours is considered to be more suitable for the treatment of meningitis. 71 Theefficacyandsafetyof Ampicillin/ Sulbactamfor MDR Acinetobacter baumannii ventilator-associated pneumonia (VAP) has been assessed in several researches with clinical improvement of 67%. [72] [73] [74] and high-dose Ampicillin/Sulbactam were comparably safe and effective treatments respect to colistin for critically ill patients with MDR A. baumannii VAP. 74 The safety and efficacy of Ampicillin/ Sulbactam was compared with colistin in the treatment of MDR A. baumannii ventilator-associated pneumonia (VAP). 75 The patients received doses of Ampicillin/ Sulbactam 9 gr/8 hours (n = 13) or colistin 3 MIU/8 hours intravenously (n = 15). Resolution of symptoms and signs occurred in 60% of the colistin group and 61.5% of the Ampicillin/Sulbactam group without any significant difference. Additionally, no significant differences in the mortality rates and in the side effects were shown.
In the Oliveira et al 73 research, 82 patients were treated with polymyxins and 85 with Ampicillin/ Sulbactam. Multiple logistic regression analysis revealed that independent predictors of mortality during treatment were the treatment with polymyxins. In this research, Ampicillin/Sulbactam appears to be more effective than polymyxins, which was an independent factor associated with mortality during treatment.
Data evaluating the safety of high dose or nontraditional dosage of Ampicillin/Sulbactam are limited. 71 Ampicillin/Sulbactam has been assessed in the bacteraemia due to A. baumannii. It was compared withimipeneminvariousstudieswithoutanysignificant difference.
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Side Effects
The adverse event profile of Ampicillin/Sulbactam is similar to the favourable profile of Ampicillin alone. 79 The most frequent adverse reaction is site pain after intramuscular injection. Another adverse reactions reported are: diarrhoea (3%), phlebitis (1.2%), and rash (,2%). Laboratory changes most commonly reported are high hepatic enzymes (serum aspartate aminotransferase, 6.2%; serum alanine aminotransferase,6.9%). 80 Haematologic abnormalities (decreased haematocrit/haemoglobin, leukopenia, lymphopenia, thrombocytopenia or increases lymphocytes, monocytes, basophils, eosinophils and platelets) decreases albumin and total proteins, increased creatinine, and the presence of red blood cells and hyaline casts in the urine are less frequent.
3,5
Clostridium difficile-associateddiseaseisasignificant nosocomial infection and is common in hospitalised patients receiving broad-spectrum antibiotics. 81 It has been reported after almost all antibiotic agents, including Ampicillin/Sulbactam, and clinicians should be aware of the possibility of C. difficile in patients presenting diarrhoea after antibiotic use.
Place of Ampicillin/Sulbactam in the Treatment of Severe Infections
Ampicillin/Sulbactam is comparable to second and third-generation cephalosporins in the treatment of lower respiratory infections. However, it is not effective against Ps. aeruginosa or intracellular bacteria that are common pathogens and must be accompanied by a macrolide or quinolone. Ampicillin/sulbactan can be used in ICU patients with community-acquired pneumonia who are not at risk for Pseudomonas infection, incombinationwithamacrolideorafluorquinolone according to IDSA/ATS guidelines (2007). 38, 39 The recent guidelines about intra-abdominal do not recommend the use of Ampicillin/Sulbactam as empiric treatment due the emergence of resistant strains of E. coli. 40 Ampicillin/Sulbactam has been shown not to be inferior to imipenem as well as piperacillin/ tazobactam in the treatment of diabetic foot infections. [60] [61] [62] In a comparative research of Ampicillin/Sulbactam vs. linezolid there was not statistically difference between both treatments although linezolid achieved higher cure rates in patients with infected ulcers and in patients without osteomyelitis. 65 However there are important limitations in the management of diabetic foot infection when the disease is due to Pseudomonas aeruginosa or Methicillin-resistant Staphylococcus aureus.
Ampicillin/Sulbactam may be an effective and safely used therapeutic option to treat severe nosocomial infections caused by multidrug-resistant (MDR) bacteria, lthough probably it needs higher doses than normally used.
Conclusions
Ampicillin/Sulbactam has a wide range of antibacterial activity that includes Gram-positive and Gramnegative aerobic and anaerobic bacteria. However, the drug is not active against Pseudomonas aeruginosa and pathogens producing extended-spectrum β-lactamases. The combination could be considered particularly active against Acinetobacter baumannii infections due to the intrinsic activity of Sulbactam. In clinical trials, sultamicillin has proved to be clinically and bacteriologically effective in adults with severe bacterial infections, bacterial infection of the lower respiratory tract, meningitis, urinary tract infections, intra-abdominal infections, diabetic foot and skin and soft tissue infections. Furthermore, side effects rarely occur being the diarrhoea the most commonly reported. Moreover, it seems to represent the alternative choice for the treatment of A. baumannii infections for carbapenem-resistant strains in the nosocomial setting.
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